Advertisement
J.P. Morgan Securities Inc. is acting as sole book-running manager of theoffering, and Deutsche Bank Securities Inc. is acting as co-lead manager.Pacific Growth Equities, LLC and Robert W. Baird & Co. Incorporated are actingas co-managers.
Advertisement
The offering will be made only by means of a prospectus. When available,copies of the preliminary prospectus relating to this offering may be obtainedby contacting: J.P. Morgan Securities Inc., 4 Chase Metrotech Center, CSLevel, Brooklyn, NY 11245 Attention: Chase Distribution & Support ServiceNortheast Statement Processing.
A registration statement relating to these securities has been filed withthe Securities and Exchange Commission, but has not yet become effective.These securities may not be sold nor may offers to buy be accepted prior tothe time the registration statement becomes effective. This press releaseshall not constitute an offer to sell or the solicitation of an offer to buynor shall there be any sale of these securities in any state in which suchoffer, solicitation or sale would be unlawful prior to their registration orqualification under the securities laws of any such state.
About AutoGenomics
AutoGenomics Inc., a privately held company based in Carlsbad, CA, hasdeveloped the first automated, microarray based multiplexing diagnosticplatform that can be used to assess disease signatures with novel genomic andproteomic markers in the area of genetic disorders, infectious disease, cancerand pharmacogenetics. With the discovery of genes and their link to variousdisease states the platform has the versatility to revolutionize the waypatients are diagnosed, monitored and managed leading to the era ofpersonalized medicine.
SOURCE AutoGenomics, Inc.
